FerdinandosSkoulidisMD

PubMed

• Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From-Mutant NSCLC Informs Potential Therapeutic Targets.
  Bingnan Zhang, Whitney Lewis, C Allison Stewart, Benjamin B Morris, Luisa M Solis, Alejandra Serrano, Yuanxin Xi, Qi Wang, Elyse R Lopez, Kyle Concannon, Simon Heeke, ...> ;JTO Clinical and Research Reports. 2024 Feb 1
• Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
  Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Jürgen Wolf, Adrian G Sacher, Toshiaki Takahashi, Suresh S Ramalingam, Christo...> ;Future Oncology. 2024 Jan 1
• Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
  Wang, K., Du, R., Myall, N., Lewis, W., Uy, N., Hong, L., Skoulidis, F., Byers, L., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M., Gibbons, D., Park, K., R...> ;Journal of Thoracic Oncology. 2024 Mar 1
• 1 citations
  Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.
  Yibirin, M., Mustafayev, K., Hosry, J., Pundhir, P., Klingen, J., Yepez Guevara, E., Granwehr, B., Kaseb, A., Naing, A., Patel, S., Shah, A., Skoulidis, F., Tawbi, H.,...> ;The American Journal of Gastroenterology. 2023 Sep 1
• 1 citations
  Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
  Kaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, Ziping T Li, Lingzhi Hong, Natalie Vokes, Yasir Y Elamin, Celyne Bueno Hume, Ferdinandos Skoulidis, Carl M Gay, George B...> ;JTO Clinical and Research Reports. 2023 Aug 1
• 11 citations
  KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
  Tony Kiat Hon Lim, Ferdinandos Skoulidis, Keith M Kerr, Myung-Ju Ahn, Joshua R Kapp, Fernando A Soares, Yasushi Yatabe> ;Lung Cancer. 2023 Oct 1
• 10 citations
  MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
  Yu Qian, Ana Galan-Cobo, Irene Guijarro, Minghao Dang, David Molkentine, Alissa Poteete, Fahao Zhang, Qi Wang, Jing Wang, Edwin Parra, Apekshya Panda, Jacy Fang, Ferdi...> ;Cancer Cell. 2023 Jul 10
• 22 citations
  Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
  Marcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, Alissa J Cooper, Neal S Akhave, Teng Zhou, Lukas Delasos, J Kevin Hicks, Mihaela Aldea, Gabriele Minuti, Jacobi H...> ;Cancer Discovery. 2023 Jul 7
• 3 citations
  Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-r...
  Mehmet Altan, Yan Wang, Juhee Song, James Welsh, Chad Tang, Nandita Guha-Thakurta, George R Blumenschein, Brett W Carter, Jeffrey S Wefel, Amol J Ghia, Debra N Yeboa, ...> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
• Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis.
  Vincenzo Formica, Cristina Morelli, Veronica Conca, Maria Alessandra Calegari, Jessica Lucchetti, Emanuela Dell'Aquila, Marta Schirripa, Marco Messina, Lisa Salvatore,...> ;Cancers. 2023 Jun 5
• 12 citations
  Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
  Maliazurina B Saad, Lingzhi Hong, Muhammad Aminu, Natalie I Vokes, Pingjun Chen, Morteza Salehjahromi, Kang Qin, Sheeba J Sujit, Xuetao Lu, Elliana Young, Qasem Al-Tas...> ;The Lancet. Digital Health. 2023 Jul 1
• 16 citations
  Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With PretreatedG12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
  Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Jürgen Wolf, Adrian G Sacher, Toshiaki Takahashi, Suresh S Ramalingam, Christo...> ;Journal of Clinical Oncology. 2023 Jun 20
• 15 citations
  Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer.
  Lingzhi Hong, Muhammad Aminu, Shenduo Li, Xuetao Lu, Milena Petranovic, Maliazurina B Saad, Pingjun Chen, Kang Qin, Susan Varghese, Waree Rinsurongkawong, Vadeerat Rin...> ;Nature Communications. 2023 Feb 8
• 71 citations
  Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASmutation: a randomised, open-label, phase 3 trial.
  Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, Anne-Marie C Dingemans, Giannis Mountzios, Miklos Pless, Jürgen Wolf, Martin Schuler, Hervé Lena, Ferd...> ;Lancet. 2023 Mar 4
• 6 citations
  Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.
  Yufei Liu, Luyang Yao, Neda Kalhor, Brett W Carter, Mehmet Altan, George Blumenschein, Lauren A Byers, Frank Fossella, Don L Gibbons, Jonathan M Kurie, Charles Lu, Fer...> ;Lung Cancer. 2022 Dec 1
• A STING operation to expose KRAS and STK11 co-mutated lung cancers.
  Ferdinandos Skoulidis, John V Heymach, Tina Cascone> ;Cancer Cell. 2022 Oct 10
• 29 citations
  Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS-mutated non-small-cell lung cancer.
  B Ricciuti, J V Alessi, A Elkrief, X Wang, A Cortellini, Y Y Li, V R Vaz, H Gupta, F Pecci, A Barrichello, G Lamberti, T Nguyen, J Lindsay, B Sharma, K Felt, S J Rodig...> ;Annals of Oncology. 2022 Oct 1
• 6 citations
  Identification ofMutations in Circulating Tumor DNA in Patients With Cancer.
  Kyaw Z Thein, Amadeo B Biter, Kimberly C Banks, Andrew W Duda, Jennifer Saam, Jason Roszik, Filip Janku, Ferdinandos Skoulidis, John V Heymach, Scott Kopetz, Funda Mer...> ;JCO Precision Oncology. 2022 Jul 1
• 5 citations
  Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.
  Steven H Lin, Heather Y Lin, Vivek Verma, Meng Xu-Welliver, Peter F Thall, Luyang Yao, Peter Y Kim, Dan S Gombos, Jitesh D Kawedia, Ritsuko Komaki, Daniel R Gomez, Quy...> ;Cancer Treatment and Research Communications. 2022 Jan 1
• 119 citations
  Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
  Vaz, V., Biagio Ricciuti, Kathryn C. Arbour, Jessica J. Lin, Amir Vajdi, Natalie I. Vokes, Lingzhi Hong, Jianjun Zhang, Michael Y. Tolstorukov, Yvonne Y. Li, Liam F. S...> ;Journal of Thoracic Oncology. 2021 Nov 2
• 17 citations
  Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib
  Joshua Bauml, Bob T. Li, Vamsidhar Velcheti, Ramaswamy Govindan, Alessandra Curioni-Fontecedro, Christophe Dooms, Toshiaki Takahashi, Andrew W. Duda, Justin I. Odegaar...> ;Lung Cancer. 2021 Oct 19
• 2 citations
  Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado.
  Ana Galan-Cobo, Christine M. Stellrecht, Emrullah Yilmaz, Chao Yang, Yu Qian, Xiao Qu, Ishita Akhter, Mary Ayres, Youhong Fan, Pan Tong, Lixia Diao, Jie Ding, Uma Giri...> ;Molecular Cancer Research. 2021 Oct 15
• 156 citations
  Structure-based classification predicts drug response in EGFR-mutant NSCLC
  Jacqulyne P. Robichaux, Xiuning Le, R. S. K. Vijayan, J. Kevin Hicks, Simon Heeke, Yasir Elamin, Heather Lin, Hibiki Udagawa, Ferdinandos Skoulidis, Hai T. Tran, Susan...> ;Nature. 2021 Sep 15
• 104 citations
  Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Journal for Immunotherapy of Cancer. 2021 Aug 1
• 574 citations
  Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
  Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy J. Price, Gerald Steven Falchook, Jürgen Wolf, Antoine Italiano, Martin Schuler, Hossein Borghaei, Fabrice Barle...> ;The New England Journal of Medicine. 2021 Jun 4
• Join now to see all

Lectures

• Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell l... 
  2019 ASCO Annual Meeting - 6/1/2019
• Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018